Novo Nordisk Secures Key EU Approval for Higher-Dose Weight-Loss Drug

Novo Nordisk has received crucial regulatory backing from Brussels, providing a positive counterpoint to recent stock market declines and heightened competitive pressures. The European Commission has approved a high-dose formulation of the blockbuster weight-loss medication Wegovy, a strategic move analysts view as essential for the pharmaceutical giant to defend its market leadership against rivals such as Eli Lilly.

A Strategic Win Amid Market Pressure

This authorization arrives at a pivotal moment for the company. Novo Nordisk’s shares have faced significant pressure, shedding approximately 48 percent of their value over a twelve-month period. This downturn was partly fueled by disappointing 2026 forecasts, which project a currency-adjusted sales decline of up to 13 percent. The EU’s green light for the enhanced Wegovy dose offers a timely operational reprieve and strengthens the company’s competitive arsenal in Europe, even as a corresponding decision from the U.S. Food and Drug Administration (FDA) remains pending.

The newly approved maintenance dose of 7.2 mg is authorized for use across all 27 EU member states. It is intended for adult patients who require additional weight reduction after standard treatment with the 2.4 mg dose. Initially, administration will involve three injections in a single session. However, Novo Nordisk has already submitted an application for a more convenient single-use pen to regulators.

Clinical Data and Therapeutic Impact

The approval is grounded in robust clinical evidence from the Phase III “STEP UP” trial. Data from this study revealed that patients on the higher 7.2 mg dose lost an average of 20.7 percent of their body weight. This compares to an average loss of 17.5 percent for those on the standard 2.4 mg regimen. Notably, the quality of the weight loss was favorable: over 80 percent of the reduction came from fat mass, while muscle function was largely preserved.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

This development is a direct response to intensifying competition, particularly from Eli Lilly’s drug Mounjaro (tirzepatide), which has been gaining market share. The more potent Wegovy variant is a central component of Novo Nordisk’s strategy to solidify its position in the European obesity treatment market.

Ongoing Innovation and Future Outlook

Concurrently, the company continues to invest in its pipeline. This week marked the initiation of a Phase 2 study for a new drug candidate, UBT251. Such research and development efforts are critical as Novo Nordisk navigates a challenging market environment.

For investors, the focus now shifts to the upcoming FDA decision in the United States regarding the high-dose formulation. Successful market introduction of the planned single-use pen, aimed at simplifying treatment for patients, will also be a key factor to monitor. This EU regulatory success provides Novo Nordisk with a strengthened foundation from which to address both near-term competitive threats and longer-term growth.